Mice were subjected to 12 h of fasting to perform ipGTT. Blood glucose level was measured with a glucometer (Accu-chek®, Roche, Basileia, Switzerland) at times 0, 15, 30, 60, 90, and 120 min after receiving an intraperitoneal glucose dose of 2 g/kg. For ipITT, after 4 h of fasting, the blood glucose level was measured (time 0) by a glucometer (Accu-chek®, Roche, Basileia, Switzerland). Mice then received an intraperitoneal administration of insulin of 1 U/kg; thereafter, glycemia was measured at 3, 6, 9, 12, and 15 min. The results were analyzed by calculating the glucose and insulin AUC using the trapezoidal integration in the GraphPad Prism® (Version 6.00, San Diego, CA, USA). Both tests were performed with 14-week-old (preoperative) and 20-week-old (postoperative) mice.
Accu chek
Manufactured by Roche
Sourced in Germany, Switzerland, United States, United Kingdom, Brazil, Australia, China, India, Spain, Canada, France, Hungary, Japan, Thailand, Belgium, Denmark
The Accu-Chek product line from Roche is a suite of blood glucose monitoring systems designed for use in clinical and personal settings. The core function of the Accu-Chek devices is to accurately measure and display blood glucose levels.
Automatically generated - may contain errors
Lab products found in correlation
Streptozotocin (stz), by Merck Group (31 mentions)
D glucose, by Merck Group (16 mentions)
Humulin r, by Eli Lilly (11 mentions)
Glucose, by Merck Group (8 mentions)
Streptozotocin (stz), by Roche (8 mentions)
Actrapid, by Novo Nordisk (6 mentions)
Elisa kit, by Crystal Chem (6 mentions)
Elisa kit, by Jiangsu Meimian (6 mentions)
Ultra sensitive mouse insulin elisa kit, by Crystal Chem (5 mentions)
Elisa, by Crystal Chem (4 mentions)
Humalog, by Eli Lilly (4 mentions)
Mouse ultrasensitive insulin elisa kit, by ALPCO (4 mentions)
Precision xtra, by Abbott (3 mentions)
Microvette tube, by Sarstedt (3 mentions)
Elisa, by Mercodia (3 mentions)
Insulin, by Novo Nordisk (3 mentions)
Humulin, by Eli Lilly (3 mentions)
Leptin, by R&D Systems (3 mentions)
S0130, by Merck Group (3 mentions)
Insulin, by Eli Lilly (3 mentions)
690 protocols using accu chek
1
Glucose and Insulin Tolerance Tests in Mice
2
Glucose Tolerance Test in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Mice were fasted overnight (6:00 p.m. to 9:00 a.m.). Briefly, scissors were used to make a small cut at the tip of the mouse tail to produce a droplet of blood, which was collected on test strips (ACCU-CHEK, Roche, Mannheim, Germany; or Prodigy) inserted into a smart view blood glucose monitor (ACCU-CHEK, Roche; or Prodigy) to analyze blood glucose levels. Scissors were cleaned with alcohol between each mouse to prevent contamination. Basal blood glucose was determined for each mouse prior to administrating J60 or vehicle via i.p. or intra-PVT. Immediately following the basal blood measurement, glucose i.p. bolus (1 g/kg body weight of 100 mg/ml glucose solution) was given, and blood glucose levels were measured at 30, 60, 90, and 120 min following the glucose injection.
3
Diabetic Wound Healing with Stem Cell Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Male Wistar rats (n = 24) weighing 300-350 g were used in this study. Rats were injected with freshly prepared STZ (Sigma-Aldrich) 65 mg/mL solution in 0.1 M citrate buffer (pH = 4.5) at a dose of 60 mg/kg i.p. Roche Accu-Chek was applied to measure blood glucose after 72 h using the blood collected from the tail vein of rats for verifying the induction of DM (glucose >300 mg/dL). The study protocol was approved by the Institutional Animal Care and Use Committee of Kaohsiung Medical University (IACUC Approval Number: 105015). All rats were housed in plastic cages with soft bedding under 12-h light/dark cycles, with free access to food and water. Rats were randomly divided into four groups (n = 6 per group) as follows: the diabetic control group (DM wound, DM-), in which the dorsal skin defect in diabetic rats was created without any treatment; the group of diabetic rats treated with ADM dressing (ABCcolla® Collagen Matrix) (DM + ADM); the group of diabetic rats treated with ASCs at 1 × 108 cells in a 1-mL injection per area (DM + ASCs); and the group of diabetic rats treated with ADM dressing seeded with ASCs at 1 × 108 cells (DM + A/A) (Fig. 4 B). The wound was then temporarily covered with transparent DuoDerm Extra Thin CGF Dressing (ConvaTec Inc.).
4
Diabetes Monitoring and Insulitis Assessment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Urine glucose concentrations (glycosuria) were measured weekly using Chemstrips (Boehringer Mannheim, Indianapolis, IN, USA). Mice with urine glucose concentration >27.75 mmol/L on two consecutive tests were defined as diabetic. Blood glucose concentrations were monitored daily by Roche ACCU-CHEK (Roche Ltd., Basel, Switzerland) after islet transplantation. Graft rejection and loss of function were defined as blood glucose levels higher than 300 mg/dL for two consecutive days. For the assessment of insulitis, pancreatic tissues were obtained from 14-week-old PBS-treated or ALA-treated NOD mice and the severity of insulitis was scored on haematoxylin–eosin stained sections (Sigma-Aldrich) and classified as described [52 (link)]. The degree of insulitis in the pancreas was evaluated by scoring 15–30 islets/mouse in a blinded fashion according the following criteria: intact islet: no mononuclear cell infiltration; peri-insulitis: mononuclear cell infiltration in <25%; intra-insulitis: mononuclear cell infiltration in 25–50% of the islet; severe insulitis: mononuclear cell infiltration in 50–75% of the islet; destructive insulitis: >75% of the islet was infiltrated.
5
Establishment of Type 2 Diabetes Rat Model
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The rats were randomly divided into 2 groups (n = 11 each): the control group and the T2DM model group. The T2DM group of rats was administered a high-fat and high-sugar diet (10% lard, 20% sucrose, 2.5% cholesterol, 1% cholic acid salt, and 66.5% conventional feed) for 12 weeks to induce insulin resistance. Then, T2DM rats were fasted for 12 h but with free access to water. After this, rats received intraperitoneal injection of 35 mg/kg streptozotocin dissolved in sodium citrate buffer (0.1 mol/L, pH 4.5). To determine successful establishment of the DM model, blood glucose levels were measured 48 h later using Roche ACCU-CHEK (Roche, Germany). Rats with blood glucose >16.7 mmol/L were considered as success T2DM model establishment. Finally, T2DM was successfully established in all 11 rats and these rats were used in downstream analysis. The control group of rats was fed with regular diet and received intraperitoneal injection of sodium citrate buffer (0.1 mol/L, pH 4.5).
6
Interval Blood Glucose Monitoring
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Random, morning blood glucose, non-fasting, concentration obtained from tail veins was determined at 4-to 8-week intervals in all groups by Roche AccuChek ® Inform (Roche Diagnostics, Indianapolis, IN).
7
Antidiabetic Potential of C.anthelminticum
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The experimental rats were divided into 7 groups each having 3 males and 3 females and they were fasted for 12 hours (for food). The animals were divided into control (glucose 2 g/kg), negative (glucose 2 g/kg + DMSO1mL/kg), and positive control (glucose 2 g/kg + standard drug: Gliclazide 200 mg/kg), and treatment groups divided on the basis of doses of FO and its fractions mentioned below).
Five doses (50, 100, 200,400, and 600 mg/kg) of each of C.anthelminticum FO and its fraction (HF, CF, and EF) were orally administered to their respective groups followed by a glucose load of 2 g/kg. Blood from the tail veins of rats was used to evaluate glucose levels at various time intervals (0, 30, 60, and 120 minutes) using a glucometer (ACCU-CHEK Roche, Switzerland) [38 (link)]. Upon completion of the OGTT study percent glycemic change between the control and test, groups were calculated [39 ].
Five doses (50, 100, 200,400, and 600 mg/kg) of each of C.anthelminticum FO and its fraction (HF, CF, and EF) were orally administered to their respective groups followed by a glucose load of 2 g/kg. Blood from the tail veins of rats was used to evaluate glucose levels at various time intervals (0, 30, 60, and 120 minutes) using a glucometer (ACCU-CHEK Roche, Switzerland) [38 (link)]. Upon completion of the OGTT study percent glycemic change between the control and test, groups were calculated [39 ].
8
Diabetic Rat Model of Ischemic Stroke
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Sprague-Dawley rats (male, 190–200 g, n=60) were purchased from Samtako
Co. (Animal Breeding Center, Osan, Korea) and randomly divided into four groups:
non-diabetic + sham, diabetic + sham, non-diabetic + MCAO and diabetic + MCAO.
Streptozotocin (40 mg/kg, Sigma, St. Louis, MO, U.S.A.) was administered by
intraperitoneal injection to induce diabetic conditions. Streptozotocin was dissolved in
10 mM citrate buffer (pH 4.6), and non-diabetic animals received citrate buffer as
vehicle. A strip-based blood glucose sensor (Accu-Chek-Roche Diagnostics, Mannheim,
Germany) was used to determine blood glucose levels, and diabetes was defined as fasting
blood glucose >300 mg/dl. Rats were kept under controlled temperature
(25°C) and lighting (14:10 light/dark cycle) conditions. All experiments were carried out
in accordance with guidelines approved by the ethics committee concerning animal research
at Gyeongsang National University. Body weight and blood glucose were measured before
MCAO.
Co. (Animal Breeding Center, Osan, Korea) and randomly divided into four groups:
non-diabetic + sham, diabetic + sham, non-diabetic + MCAO and diabetic + MCAO.
Streptozotocin (40 mg/kg, Sigma, St. Louis, MO, U.S.A.) was administered by
intraperitoneal injection to induce diabetic conditions. Streptozotocin was dissolved in
10 mM citrate buffer (pH 4.6), and non-diabetic animals received citrate buffer as
vehicle. A strip-based blood glucose sensor (Accu-Chek-Roche Diagnostics, Mannheim,
Germany) was used to determine blood glucose levels, and diabetes was defined as fasting
blood glucose >300 mg/dl. Rats were kept under controlled temperature
(25°C) and lighting (14:10 light/dark cycle) conditions. All experiments were carried out
in accordance with guidelines approved by the ethics committee concerning animal research
at Gyeongsang National University. Body weight and blood glucose were measured before
MCAO.
9
Glucose Tolerance Test in Rats
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Immediately after the basal metabolic rate measurement, glucose was administered by gavage (2 g/kg body weight; 50% solution). Blood glucose levels were determined by small clipping of the rat tail, immediately before (0 min) the glucose challenge, as well as at 30, 60, and 120 min thereafter. Blood glucose levels were determined using an ACCU-CHEK (Advantage Glucose Analyzer, Roche Diagnostics Corporation, IN, USA).
10
Glucose Tolerance in Tip60 Haploinsufficient Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
WT C57BL/6J mice (8 weeks; Charles River Laboratories) and Tip60+/− mice [11] (link), [17] that had been backcrossed to C57BL/6J for 12 generations, were age-matched and fed standard chow until age 11 weeks, and subsequently fed LFD (10% kcal% fat, Research Diet D12450B) or HFD (45% kcal% fat, Research Diet D12451) for 19 weeks. Intraperitoneal glucose tolerance test (IP-GTT) was performed as described [18] . In short, mice (age 29 weeks) were fasted overnight, glucose was injected intraperitoneally (0.5 g/kg body weight) and blood glucose levels were measured before, and at multiple time points after glucose injection (Accu-chek, Roche). All mouse study protocols were approved by the Utrecht University Ethical Committee for Animal Experimentation (protocol 2010.III.01.008) and were in accordance with current Dutch laws on animal experimentation.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!